• Sony Penumaka
• Shagufa Arsheen Mohammad
• Satya Sri Valli Tottala
• Sri Lasya Priya Cheruvu
• S. Sarath Ajay Kumar, Immadi Reshma Naidu, Padmalatha Kantamaneni

Schizophrenic patients often use alcohol and other drugs, contributing to their disorder's morbidity. In individuals with schizophrenia, the lifetime prevalence of substance use disorders (SUDs) is close to 50%. With a large proportion of poly-substance users, the most commonly used substances are cannabis, alcohol, and nicotine. The emotional and financial toll that schizophrenia has on individuals, families, and the mental health system as a whole is significantly increased by these comorbid diseases. Standard antipsychotic drugs do not limit substance use, but atypical antipsychotics like clozapine may decrease it. Clozapine's beneficial effect in patients with comorbid schizophrenia and substance use disorders may be due to its ability to ameliorate deficits in dopaminergic neuronal projections. The aim of the current article is to review clozapine's effectiveness in treating SUD in schizophrenia patients. Different studies were taken into account and reviewed. There is more evidence of clozapine's impact on SUD, particularly when comparing it to first-generation antipsychotics in polydrug users.

schizophrenia, substance use disorder (SUD), atypical antipsychotics, relapse, and clozapine.

"A review on the impact of clozapine on relapses in substance abuse among schizophrenia patients", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.11, Issue 2, page no.c439-c445, February-2024, Available :http://www.jetir.org/papers/JETIR2402252.pdf

"A review on the impact of clozapine on relapses in substance abuse among schizophrenia patients", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.11, Issue 2, page no. ppc439-c445, February-2024, Available at : http://www.jetir.org/papers/JETIR2402252.pdf